Drug Profile
Research programme: apolipoprotein A-I stimulants - KineMed
Alternative Names: Acute HDL therapeutic - KineMed; Apo-A1 mimetic peptide for atherosclerosis - KineMed; ApoA-I mimetic lead compound for atherosclerosis and heart disease - KineMed; FX-5ALatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator KineMed
- Class Peptides
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Atherosclerosis; Cardiovascular disorders
Highest Development Phases
- No development reported Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (IV)
- 11 Apr 2012 Research programme: apolipoprotein A-I stimulants - KineMed is available for licensing as of 11 Apr 2012. http://www.kinemed.com